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https://doi.org/10.1016/j.cgh.2020.10.009The World Health Organization declared coronavi-rus disease-2019 (COVID-19) a global pandemic
in March 2020. Since then, there are more than 34
million cases of COVID-19 leading to more than 1 million
deaths worldwide. Numerous studies suggest that celiac
disease (CeD), a chronic immune-mediated gastrointes-
tinal condition triggered by gluten, is associated with
an increased risk of respiratory infections.1-3 However,
how it relates to the risk of COVID-19 is unknown. To
address this gap, we conducted a cross-sectional study
to evaluate whether patients with self-reported CeD are
at an increased risk of contracting COVID-19.
Methods
This study was conducted between March and June
2020. Participants of all ages with a self-reported CeD
diagnosis and those without CeD from different countries
including Argentina, Australia, Canada, Italy, Mexico,
New Zealand, Spain, Uruguay, and the United States were
recruited through local CeD associations, electronic
newsletters, and social media. Participants completed a
web-based survey consisting of 41 items, which was
translated into Spanish and Italian using the approach
proposed by Mallinckrodt and Wang.4 Data on de-
mographics, gluten-free diet (GFD), symptomatology, and
COVID-19 testing were collected using RedCap.
Statistical analyses were carried-out using SPSS
version 25 (IBM, Armonk, NY). Continuous and categor-
ical variables were compared using the Mann-Whitney U
test and chi-square test. Logistic regression was per-
formed to assess the impact of different factors on the
likelihood of reporting a positive COVID-19 test
(dependent variable). Independent variables includedCeD diagnosis, age, gender, comorbidities, GFD adher-
ence, extra precautions, and previous COVID-19 expo-
sure. The unadjusted and adjusted odds ratios were
reported with their 95% confidence intervals.Results
A total of 18,022 participants completed the survey.
From them, 10,737 had self-reported CeD; they were
older (mean, 32 vs 41 years; P < .01) and had a higher
proportion of females when compared with the control
group (85% vs 80%; P < .001).
CeD was confirmed by duodenal biopsy in 7506 pa-
tients (69.9%). Thirty-two percent of patients with CeD
had persistent symptoms. A strict GFD was reported by
65.7% and 3.9% of patients with CeD and control subjects,
respectively. A greater proportion of patients with CeD
had comorbidities including respiratory (6.6% vs 3.7%; P
< .001), cardiac (3.5% vs 1.9%; P < .001), and diabetes
(3.8% vs 2.5%; P< .001) compared with control subjects.
Patients with CeD were significantly less likely to
have been tested for COVID-19 (4.5% vs 6.6%; P < .001)
and to have been exposed to COVID-19 (1.6% vs 4%; P <
.001) compared with control subjects. Out of 940 par-
ticipants tested for COVID-19, 8.7% reported a positive
test. There was no difference in the odds of having a
positive test for COVID-19 in CeD compared with control
subjects (9.4% vs 8.1%; odds ratio, 1.18; 95% confidence
interval, 0.75–1.84).
Table 1. Likelihood of Positive COVID-19 Test in CeD and
Non-CeD Populations









CeD 1.3 (0.8–2) .3 1.4 (0.5–3.5) .5
Female gender 1.7 (1–2.9) .07 2.4 (0.9–6.5) .08
Age 1 (0.97–1) .3 1 (0.9–1) .5
Gluten-free dieta 1.1 (0.7–1.8) .6 0.9 (0.4–2.5) .9
Comorbiditiesb 0.9 (0.5–1.6) .7 1.2 (0.5–2.7) .7
Extra precautionsc 0.6 (0.4–1.1) .1 1.4 (0.8–2.7) .3
Previous exposure
to COVID-19
15.3 (8–29) < .001 16.7 (7.7–36) < .001
CeD, celiac disease; CI, confidence interval; OR, odds ratio.
aDichotomized strict versus not-strict gluten-free diet.
bCardiovascular, respiratory, diabetes, autoimmune diseases.
cExtensive personal protect equipment use and social isolation.
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difference in the odds of contracting COVID-19 in pa-
tients with and without biopsy confirmation of CeD (9%
vs 10%; P ¼ .65), symptomatic versus not-symptomatic
CeD (11% vs 7%; P ¼ .13), or those adopting a strict-
GFD versus not-strict-GFD (9% vs 10%; P ¼ .74).
Twenty-eight percent of CeD reported taking extra
safety precautions for COVID-19; however, this did not
change the likelihood of a positive COVID-19 test.
Exposure to a COVID-19 contact was the only factor
increasing the odds of a positive test (Table 1).
Discussion
To our knowledge, this is the first large-scale study to
examine risk of COVID-19 in CeD compared with non-
celiac population. We found that patients with CeD had a
similar odds of contracting COVID-19 when compared
with the control subjects. The presence of comorbidities,
which was identified as an important predictor of
morbidity and mortality associated with COVID-19,5 was
more frequent in CeD than control subjects. However,
this did not result in higher odds of a positive COVID-19
test in CeD. We hypothesized that adopting a strict-GFD
and having fewer symptoms6 would decrease the odds
of contracting COVID-19 in CeD; however, this was not
confirmed in our analyses. It is of common knowledge7
that previous exposure to someone with COVID-19 in-
creases the risk of contracting COVID-19,8 and this was
confirmed in our study. However, patients with CeD
were less exposed to COVID-19 than control subjects,
which may have influenced the results.
We acknowledge the presence of limitations related
to the design of our study, which used a web-based
survey for data collection, and therefore, the source ofinformation provided by participants cannot be
confirmed. The study was not designed to assess differ-
ences in COVID-19-related severity outcomes, and it is
our hope that the ongoing international SECURE-Celiac
registry (www.covidceliac.org) will further address this.
In conclusion, patients with CeD have similar odds of
contracting COVID-19 and may not need to take addi-
tional precautions to prevent exposure aside from that
recommended to the general public. Longitudinal studies
using repeated measurements will contribute to a better
understanding on whether the risk of contracting COVID-
19 in CeD changes over time.References
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